We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn about our cookie policy.
Sigma-Aldrich Pas Kinase Inhibitor Bioe
List Price $281.88 Your Price $281.88
Sigma-Aldrich Pas Kinase Inhibitor Bioe-1115 - SIAL (Additional S&H Or Hazmat Fees May Apply)
NETA PART: SIAL-5323060001
MFG.PART: 5323060001
UNSPSC: 12352200
Manufacturer: Sigma-Aldrich


Assay
≥97% (HPLC)
Quality Level
100
Form
powder
Manufacturer/Tradename
Calbiochem®
Storage Condition
OK to freeze
protect from light
Color
yellow
Solubility
DMSO: 50 mg/mL
Storage Temp.
2-8°C
General Description
A cell-permeable quinoxaline-carboxylic acid compound that acts as a selective PAS kinase/PASK inhibitor (IC50~ 4 nM) with little or no potency against a panel of 49 other kinases (IC50≥ 10 µM) and effectively inhibits cellular PASK-T307 autophosphorylation (IC50~ 1 µM; 16 H drug treatment in PASK-transfected HEK293T cultures with 1% FBS). Similar to siRNA-mediated PASK knockdown, BioE-1115 treatment is shown to effectively prevent sterol regulatory element binding protein SREBP-1c maturation without affecting Akt/mTOR pathway signaling, resulting in impaired cellular SREBP transcription activity in HepG2 cultures (% inhibition/[drug] = 40%/30 µM & & 65%/50 µM by SRE-Luc reporter assay; overnight drug treatment prior to 100 nM insulin stimulation for 6 H). Oral administration is reported to effectively reduce high-frucose diet/HFrD-induced dyslipidemia (% reduction of liver triglyceride/serum triacylglyerol/dose = 48/26/30 mg kg-1& 63/55/100 mg kg-1; Daily oral dosage administered in the last wk of a 3 wk HFrD period, followed by a 24 H fasting and a 12 refed period prior to tissue collection) and insulin resistance (% reduction of serum glucose/insulin/dose = 23/14/30 mg kg-1& 28/31/100 mg kg-1) in rats by selectively suppressing SREBP-1 maturation and thereby inhibiting SREBP-1c, but not SRREBP-2, target genes transcription in liver, but not in abdominal fat or gastrocnemius musclein vivo(%Gpat1/Fasn/Scd1/Acc1/FaemRNA reduction/plasma [BioE-1115] in µg/mL/dose = 40/34/36/27/34/2.07/10 mg kg-1, 59/56/51/48/54/7.65/30 mg kg-1, 76/5967/62/74/42.2/100 mg kg-1) without affecting liver or body weight.A cell-permeable, orally available, non-toxic quinoxaline-carboxylic acid based compound that acts as a highly potent, selective, and reversible inhibitor of Per-Arnt-Sim Kinase (PASK; IC50~ 4 nM). Exhibits excellent selectivity over 49 other kinases (IC50>10 µM) and displays about 2,500-fold greater potency for PASK over casein kinase 2α. Blocks PASK autophosphorylation at Thr307 in a dose-dependent manner (IC50~ 1 µM) without affecting the insulin-induced phosphorylation of either Akt or S6K. Effectively blocks the maturation of SREBP-1 in hepatic tissue of high fructose fed wild-type Sprague-Dawley rats. Shown to normalize hepatic and serum triglyceride levels, reduce blood glucose levels, and partially reverse insulin resistance in animal models (30 mg/kg. p.o.).Please note that the molecular weight for this compound is batch-specific due to variable water content.BioE-1115, PASKi
Biochem/Physiol Actions
Cell permeable: yesPrimary TargetPASK
Warning
Toxicity: Standard Handling (A)Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.Other Notes
Wu, X., et Al. 2014.Cell Rep. 8,242.CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany| SKU | SIAL-5323060001 |
|---|---|
| Supplier Part Number | 5323060001 |
| UM | EA |
| UNSPSC | 12352200 |
| Manufacturer | Sigma-Aldrich |
| ProductLine | SIAL |
| Qty | 1 |
| MinOrderQty | 1 |
| Weight | 10.000000 |
| Lead Time | 9 |
| Hazardous | N |
| Energy Star | No |
| Green | No |
| Controlled | N |

